Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 591 • 2014 ACR/ARHP Annual Meeting
The Fat Spondyloarthritis Spine Score (FASSS) Independently Predicts Radiographic Progression in Patients with Ankylosing Spondylitis
Susanne Juhl Pedersen¹, Stephanie Wichuk², Praveena Chiowchanwisawakit³, Zheng Zhao⁴, Robert GW Lambert⁵ and Walter P. Maksymowych⁶, ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Mahidol University, Bangkok, Thailand, ⁴PLA General Hospital, Beijing, China, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada
The Fat Spondyloarthritis Spine Score (FASSS) independently predicts radiographic progression in patients with ankylosing spondylitis. Background/Purpose Vertebral corner fat lesions have been shown to be…
Abstract Number: 536 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing
Joachim Sieper¹, Jürgen Braun², Xenofon Baraliakos², Dominique L. Baeten³, Maxime Dougados⁴, Paul Emery⁵, Atul A. Deodhar⁶, Brian Porter⁷, Mats Andersson⁸, Shephard Mpofu⁸ and Hanno Richards⁹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁵University of Leeds, Leeds, United Kingdom, ⁶Oregon Health and Sciences University, Portland, OR, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Previous data indicate that interleukin (IL)-17, a key pro-inflammatory cytokine, might play a role in the pathogenesis of ankylosing spondylitis (AS). We assessed the…
Abstract Number: 2832 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study
Elisabeth Lie^1,2, Lars Erik Kristensen³, Helena Forsblad-d'Elia¹, Johan Askling⁴ and Lennart T. Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose For rheumatoid arthritis it is well established that co-medication (co-med) with methotrexate (MTX) increases the efficacy and drug survival of TNF inhibitors (TNFi), while…
Abstract Number: 2564 • 2014 ACR/ARHP Annual Meeting
Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis
Soo Min Ahn, Bin Yoo, Chang-Keun Lee, Yong-Gil Kim, Seokchan Hong, Seung-Hyeon Bae and Doo-Ho Lim, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The prevalence of concurrent Ankylosing spondylitis (AS) and inflammatory bowel disease, either Crohn's disease (CD) or Ulcerative colitis (UC), is estimated at 5-10%. Up…
Abstract Number: 1285 • 2014 ACR/ARHP Annual Meeting
Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment – Results of a Large Non-Intervention Study
Gustavo Citera¹, Edgardo Smecuol², Alberto Millán³, Manuel Robles⁴ and Ruben Mantilla⁵, ¹Universidad de Buenos Aires, Buenos Aires, Argentina, ²Hospital Municipal de Gastroenterología, Buenos Aires, Argentina, ³Hospital Universitario de Caracas, Caracas, Venezuela, ⁴Centro Médico Toluca, Toluca, Mexico, ⁵Clínica de Artritis y Rehabilitación (CAYRE), Bogota, Colombia
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the long established first-line treatment for the management of pain associated with rheumatic diseases but carry a risk of…
Abstract Number: 589 • 2014 ACR/ARHP Annual Meeting
Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa
Lennart TH Jacobsson¹, Tomas Husmark², Elke Theander³, Kenneth Henriksson⁴, Katharina Büsch⁵ and Martin Johansson⁵, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Rheumatology, Falu Hospital, Falun, Sweden, ³Skane University Hospital Malmö, Lund University, Malmö, Sweden, ⁴Rheumatology city clinic, Stockholm, Sweden, Stockholm, Sweden, ⁵AbbVie AB, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose The ASAS axial SpA classification criteria was published in 2009 but so far there has been limited research on axial SpA patients in clinical…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
Abstract Number: 2618 • 2014 ACR/ARHP Annual Meeting
Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study
Denis Poddubnyy¹, Kay-Geert Hermann¹, Johanna Callhoff², Joachim Listing² and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany
Background/Purpose Ustekinumab – a fully human monoclonal antibody against interleukins 12 and 23 – has been shown to be effective in reduction of symptoms of…
Abstract Number: 2561 • 2014 ACR/ARHP Annual Meeting
Low Cardio-Respiratory Fitness Is Associated with Increased Arterial Stiffness in Patients with Ankylosing Spondylitis
Inger Jorid Berg¹, Anne Grete Semb², Silje H. Sveaas^3,4, Camilla Fongen³, Désirée van der Heijde^3,5, Tore K. Kvien³, Hanne Dagfinrud³ and Sella A. Provan³, ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Health Sience, University of Oslo, Oslo, Norway, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose We have previously shown that patients with ankylosing spondylitis (AS) have lower cardio-respiratory fitness (CRF) than population controls. CRF is inversely associated to risk…
Abstract Number: 1159 • 2014 ACR/ARHP Annual Meeting
Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic
Liliana Sedova^1,2, Monika Urbanova³, Jiri Stolfa^2,3, David Suchy⁴, Andrea Smrzova⁵, Tomas Mlcoch⁶, Jiri Klimes⁷ and Tomas Dolezal⁷, ¹rheumatology, Institute of Rheumatology, Prague, Czech Republic, ²Clinic of Rheumatology, Charles University Prague, Prague, Czech Republic, ³Inpatients´ Clinic, Institute of Rheumatology Prague, Prague, Czech Republic, ⁴Department of Clinical Pharmacology, Rheumatology, University hospital Plzen, Plzen, Czech Republic, ⁵3rd internal clinic, University hospital Olomouc, Olomouc, Czech Republic, ⁶Institute of Health Economics and Technology Assessment, Prague, Dominica, ⁷Institute of Health Economics and Technology Assessment, Charles University, Prague, Czech Republic
Background/Purpose To describe the quality-of-life (QoL), productivity impairment, clinical indicators and health care costs in relationship to functional status described by Bath Ankylosing Spondylitis Functional…
Abstract Number: 588 • 2014 ACR/ARHP Annual Meeting
Blacks with As Have Greater Disease Severity Than Whites
Farokh Jamalyaria¹, Michael M. Ward², MinJae Lee³, Lianne S. Gensler⁴, Laura A. Diekman⁵, Mohammad H. Rahbar⁶, Amirali Tahanan⁶, Shervin Assassi⁷, Michael H. Weisman⁸ and John D. Reveille^9,10, ¹University of Texas Health Science Center at Houston, Houston, TX, ²Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, ³Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶The University of Texas Health Science Center at Houston, Houston, TX, ⁷Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁰Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
Background/Purpose : To compare clinical parameters in African American (AA) patients with ankylosing spondylitis (AS) to white patients. Methods: 539 AS patients (47 B, 492…
Abstract Number: 318 • 2014 ACR/ARHP Annual Meeting
HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Rajni Srivastava¹, Shikha Agnihotry², Rakesh Aggarwal³ and Amita Aggarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Bioinformatics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: HLA-B27 has a high degree of genetic polymorphism, with more than 105 known subtypes. Enthesitis Related Arthritis (ERA) is most common form of Juvenile Idiopathic Arthritis…
Abstract Number: 2617 • 2014 ACR/ARHP Annual Meeting
No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study
Aikaterini I. Arida¹, Maria Konsta¹, Alexios Iliopoulos², Maria Tektonidou³, George Konstantonis¹, George D. Kitas⁴, Athanasios D. Protogerou¹ and Petros P. Sfikakis¹, ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Department of Rheumatology, Veterans Administration Hospital, Athens, Greece, ³First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴The Dudley Group of Hospitals NHS Foundation Trust, Dudley, and Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Background/Purpose: Chronic inflammatory arthritis is associated with increased cardiovascular disease (CVD) risk. The mechanisms behind this link include chronic inflammation, comorbidities and disease-related drugs. CV…
Abstract Number: 2553 • 2014 ACR/ARHP Annual Meeting
Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study
Nisha Nigil Haroon¹, Eva Szabo², Janet Raboud³, Ammepa Anton⁴, Robert Josse¹, Robert D. Inman¹ and Angela Cheung¹, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, UHN, TOronto, ON, Canada, ³Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose Patients with ankylosing spondylitis (AS) have high fracture risk. BMD, bone microarchitecture and strength determine fracture risk. However, in AS, DXA-based BMD measurements of…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.